PTPN1

Chr 20AD

protein tyrosine phosphatase non-receptor type 1

Also known as: PTP1B

This protein tyrosine phosphatase dephosphorylates key signaling molecules including insulin receptor kinase, EIF2AK3/PERK in the endoplasmic reticulum unfolded protein response, and growth factor receptors. Autosomal dominant mutations cause insulin resistance susceptibility. The gene shows high constraint against loss-of-function variants (pLI 0.81, LOEUF 0.38), indicating that complete loss of function is likely not tolerated.

Summary from RefSeq, OMIM, UniProt
Research Assistant →

Primary Disease Associations & Inheritance

{Insulin resistance, susceptibility to}MIM #125853
AD
0
Active trials
50
Pubs (1 yr)
12
P/LP submissions
8%
P/LP missense
0.38
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryPTPN1
Population Constraint (gnomAD)
Moderately constrained gene (pLI 0.81) — some intolerance to loss-of-function variants.
📋
ClinVar Variants
12 unique Pathogenic / Likely Pathogenic· 26 VUS of 59 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint
0.38LOEUF
pLI 0.813
Z-score 3.98
OE 0.18 (0.090.38)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint
2.79Z-score
OE missense 0.51 (0.440.59)
129 obs / 254.2 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios
LoF OE0.18 (0.090.38)
00.351.4
Missense OE0.51 (0.440.59)
00.61.4
Synonymous OE0.95
01.21.6
LoF obs/exp: 5 / 27.5Missense obs/exp: 129 / 254.2Syn Z: 0.41
DN
0.5379th %ile
GOF
0.6737th %ile
LOF
0.4430th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and loss-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median · 1 literature citation
LOF1 literature citation · LOEUF 0.38

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

GOFGain-of-function mutations in PTPN11, encoding the tyrosine phosphatase SHP2, cause approximately 50% of Noonan syndrome cases.PMID:17143285
LOFLoss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome.PMID:21533187

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

59 submitted variants in ClinVar

Classification Summary

Pathogenic9
Likely Pathogenic3
VUS26
Likely Benign5
Benign2
9
Pathogenic
3
Likely Pathogenic
26
VUS
5
Likely Benign
2
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
1
1
7
0
9
Likely Pathogenic
0
0
3
0
3
VUS
0
25
1
0
26
Likely Benign
0
3
1
1
5
Benign
0
0
0
2
2
Total12912345

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

PTPN1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →